Emergence and Spread of Chlamydia trachomatis Variant, Sweden

Björn Herrmann, Anna Törner, Nicola Low, Markus Klint, Anders Nilsson, Inga Velicko, Thomas Söderblom, and Anders Blaxhult

A variant of Chlamydia trachomatis that had escaped detection by commonly used systems was discovered in Sweden in 2006. In a nationwide study, we found that it is now prevalent across Sweden, irrespective of the detection system used. Genetic analysis by multilocus sequence typing identified a predominant variant, suggesting recent emergence.

In 2006 a new variant of Chlamydia trachomatis (nvCT) was discovered in Sweden (1). Because of a 377-bp deletion in the target sequence for amplification, the variant had escaped detection by 2 widely used nucleic acid amplification tests, Abbott m2000 (Abbott Laboratories, Abbott Park, IL, USA) and Cobas Amplicor/TaqMan48 (Roche Diagnostics, Basel, Switzerland) (1, 2). The other test commonly used in Sweden, ProbeTec ET (Becton Dickinson [BD], Franklin Lakes, NJ, USA), detects the new variant because it uses a different DNA target sequence in the cryptic plasmid (3). The nvCT has now been reported from several of Sweden’s 21 counties (Figure 1). The aim of this study was to provide a national overview of the characteristics and extent of the new chlamydia variant through examination of surveillance trends, microbiologic laboratory data, and genetic analysis of new variant strains.

The Study

We examined national surveillance data reported to the Swedish Institute for Infectious Disease Control (Smittskyddsinstitutet) about chlamydia cases detected and the number of chlamydia tests performed. Trend analysis from 2004 to 2006 included only data for the first 6 months of each year to avoid any influence of changes in detection systems; some counties introduced different detection systems in late 2006 in response to the emergence of nvCT. The statistical methods are described in the online Technical Appendix (available from http://www.cdc.gov/EID/content/14/9/1462-Techapp.pdf). The total number of chlamydia cases detected in Sweden in the first 6 months of 2006 was lower than that in 2005, and the proportion of tests that were positive also fell (Table 1). From 2004 to 2005, there was a relative reduction of 3.4% (95% confidence interval [CI] 5.8–1.0) in chlamydia positivity in laboratories using the Abbott or Roche methods (p = 0.006) but no change in the proportion of positive samples in laboratories using the BD test system (−0.4%, 95% CI −4.2 to +3.5). During the first 6 months of 2005 and 2006, the positivity rates of samples tested by Abbott or Roche systems fell further; samples tested that used the BD system remained stable. The estimated difference in proportions of chlamydia-positive samples in counties that used Abbott or Roche tests compared with counties that used the BD method was −9.5% (95% CI −14.1 to −4.7, p = 0.0005), after baseline differences and county differences in testing were controlled for.

We conducted microbiologic analyses on consecutive samples that were collected from 12 counties in late 2006 and early 2007. Cases of nvCT were identified by testing specimens with additional methods using alternative detection systems.
quency targets (online Technical Appendix). The propor-
tion of nvCT ranged from 20% to 64% in the 8 counties that
used Abbott or Roche detection systems, compared with
7% to 19%, respectively, for counties that used BD tests
(Figure 1). Additional data about gender, age, and clini-
cal setting of diagnoses were available for 600 chlamydia-positive patients in the 4 counties using the BD system
(Table 2). The proportion of nvCT cases varied between
clinics (p = 0.020) and was higher at youth and venereal
disease clinics than at antenatal and gynecology clinics.
This variance might be because persons seeking treatment
in these settings have higher levels of risk taking and more
frequent changes in partners (4). There was no evidence of
differences in the proportion of cases by gender (p = 0.103)
or age (p = 0.558) because of nvCT.

Genetic characterization with a new high-resolution
genotyping system (5) was performed on 48 specimens of
nvCT from 2 counties that used the BD test system (n =
21); 2 counties that used Roche and Abbott systems (n =
18); and 9 specimens from Norway, Ireland, and France
(online Technical Appendix). The nvCT showed a new ge-
netic variant in the chromosomal target region hctB com-
pared with previous findings in wild-type strains and thus
constitutes a separate clone with the designation 21 (hctB),
19 (CT058), 1 (CT144), 2 (CT172), and 1 (phoB) in our
system. All 48 specimens tested were of genotype E, and
46 were identical in the ompA gene to the reference strain E/
Bour. The divergent specimens were from 2 persons known
to be sexual partners and differed in a single nucleotide po-
sition. In the other 5 target genes, altogether comprising
some 5,500 bp, all 48 specimens were identical.

**Conclusions**

Our study was a national systematic overview includ-
ing surveillance, demographic, microbiologic, and genetic
data about the emergence and spread of a mutant strain of *C.
trachomatis* in Sweden. A fall in the proportion of positive
chlamydia test results in counties using Abbott or Roche test
systems began in 2005 and continued in 2006, whereas posi-
tivity rates in counties using BD tests did not change. The
mutant strain has now spread throughout Sweden. Notably,
the new variant has scarcely been found outside Sweden (6),
indicating that we need to improve our understanding of the
sexual networks through which chlamydiae spread (7).

Our analysis suggests that widespread transmission of
nvCT is recent, even if the mutation itself occurred some
time ago, because 46 of 48 specimens from different places
had identical sequences when we used a highly discrimina-
tory multilocus sequence typing system (5). This hypo-
thesis is supported by the lack of diversification in the mutant
strains compared with the high degree of sequence varia-
tion in other sample collections that we have analyzed (5;
and unpub. data). We expect new nucleotide substitutions
to occur over time.

The area in Sweden in which nvCT originated is not
known, but the consistently high proportion of nvCT found
in the county of Dalarna suggests that the mutant might
have been present in this region for longer than in other
counties studied. nvCT comprised 64% of chlamydia-positi-
ve specimens over the study period in Dalarna as a whole,
and up to 78% in some localities (7); elsewhere in Sweden
(8–10) and worldwide (11,12), genotype E strains of dif-
ferent subvariants comprise >40% of chlamydia-positive
specimens in heterosexual populations. These data might
indicate that the high proportion of nvCT is not only a re-
sult of accumulation of chlamydia cases when diagnostics
failed and treatment and contact tracing were inadequate.
Further studies will be needed to determine whether nvCT
also has a selective advantage that might outcompete the
wild-type bacterium over time.

The emergence of this mutant strain of a sexually trans-
mittted pathogen has implications for public health practice.
A recent study estimates that some 8,000 chlamydia cases

| Table 1. Numbers of chlamydia tests, positive results, and change in positivity rates, Sweden, 2004–2006 |
|------------------|------------------|------------------|------------------|
| Diagnostic test* | No. counties | No. positive results/total no. tests (%) in first 6 mo | 2004 | 2005 | 2006 |
|------------------|------------------|------------------|------------------|------------------|
| Abbott/Roche | 14 | 11,721/150,080 (7.8) | 11,111/147,311 (7.5) | 10,236/152,960 (6.7) |
| Becton Dickinson | 8 | 4,262/54,260 (7.9) | 5,220/66,728 (7.8) | 3,363/43,189 (7.8) |
| All tests | 21 | 15,983/204,340 (7.8) | 16,331/214,039 (7.6) | 13,599/196,149 (6.9) |
| *One county used both Roche and Becton Dickinson tests. |

<p>| Table 2. Distribution of cases of nvCT by gender, age, and clinic category in 4 selected counties that used the Becton Dickinson system* |
|------------------|------------------|------------------|</p>
<table>
<thead>
<tr>
<th>Factor</th>
<th>% nvCT (n/N)</th>
<th>p value†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>Male</td>
<td>16 (45/273)</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>12 (39/327)</td>
</tr>
<tr>
<td>Age, y</td>
<td>15–19</td>
<td>14 (23/162)</td>
</tr>
<tr>
<td></td>
<td>20–24</td>
<td>16 (44/279)</td>
</tr>
<tr>
<td></td>
<td>25–29</td>
<td>11 (11/98)</td>
</tr>
<tr>
<td></td>
<td>&gt;30</td>
<td>10 (6/59)</td>
</tr>
<tr>
<td>Clinic</td>
<td>Venereal disease</td>
<td>15 (19/129)</td>
</tr>
<tr>
<td></td>
<td>Youth clinics</td>
<td>19 (39/210)</td>
</tr>
<tr>
<td></td>
<td>Gynecology</td>
<td>9 (13/150)</td>
</tr>
<tr>
<td></td>
<td>Antenatal/general practice</td>
<td>8 (6/77)</td>
</tr>
<tr>
<td></td>
<td>Others</td>
<td>21 (7/34)</td>
</tr>
<tr>
<td>*nvCT, new variant of Chlamydia trachomatis; n, number of nvCT cases detected; N, total number of C. trachomatis cases detected.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>†Determined by χ² test.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
escaped detection in 2006 (7). This would have resulted in an ≈20% increase in reported chlamydia cases. Actual national figures for 2007 confirm such an increase, and the number of reported chlamydia cases has reached an all-time high in Sweden (Figure 2). Chlamydia infections, caused not only by nvCT, continue to rise (13,14), but the areas most heavily affected by the spread of nvCT have been in much the same situation as before chlamydia was first recognized as a pathogen. Failure to detect the nvCT over time have resulted in episodes of complicated infection all over the country, leading to ectopic pregnancies and infertility. Research is now needed to determine whether sequelae associated with chlamydia occur disproportionately in counties where test systems fail to diagnose the nvCT. The ability of this new variant to escape detection for so long shows that developers of future diagnostic tests need to take into account the structure and function of genomes when selecting appropriate target nucleic acid sequences in microorganisms. Currently, there are unique opportunities for research that could lead to insights into the immunobiology, transmission, and consequences of C. trachomatis.

Acknowledgments

Prevalence data on the new variant of C. trachomatis or samples for analysis were provided from different counties. We thank Kenneth Persson, Ida Björklund, Torvald Ripa, Jens Björkman, Andreas Mattussek, Christina Lundberg, Hans Fredlund, Maria Rotzén Östlund, Britta Loré, and Barbro Almqvist. Amir Moghaddam generously contributed 6 specimens from Oslo, Norway, Yvonne Lynagh kindly provided 2 specimens from Ireland, and Bertille Barbeyrac provided 1 sample from France.

Research on the new variant of C. trachomatis was supported by grants from Roche Molecular Diagnostics and Becton Dickinson.

Dr Herrmann is a microbiologist and associate professor at the University Hospital in Uppsala, Sweden. His major research interests are diagnostics and epidemiology of Chlamydia infections and the development of molecular methods for detecting different bacteria and viruses.

References


The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated.